The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Voronina T.A.

NII farmakologii im. V.V. Zakusova RAMN, Moskva

Ivanova E.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Combined administration of mexidol with known medicines

Authors:

Voronina T.A., Ivanova E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4): 115‑124

DOI: 10.17116/jnevro2019119041115

Read: 443604 times

Download PDF (RU)
Contact the author
Table of contents

COMBINED ADMINISTRATION OF MEXIDOL WITH KNOWN MEDICINES
COMBINED ADMINISTRATION OF MEXIDOL WITH KNOWN MEDICINES

To cite this article:

Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):115‑124. (In Russ.)
https://doi.org/10.17116/jnevro2019119041115

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Adju­vant pharmacological modu­lation with Cyto­flavin in reha­bilitation at stages 2—3 in patients with acute cere­bral insu­fficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
A personalized approach to the diagnosis of epilepsy in obese children. Labo­ratory Service. 2025;(1):5-12
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
Effi­cacy of combined therapy of prurigo adultorum with application of temgicoluril anxiolytic. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):210-216
10-year dyna­mics of cardiovascular status in combination with coro­nary angiography data in men of working age in the Arctic region of resi­dence and the south of the Tyumen region. Russian Journal of Preventive Medi­cine. 2025;(4):30-38
Abstract:

This review summarizes the available data on the combined administration of mexidol with medicines of different pharmacotherapeutic groups. Mexidol has a multifaceted mechanism of action and exhibits a wide range of pharmacological effects. It enhances therapeutic effects of a variety of drugs in research and clinical settings, boosts the effectiveness of therapy prescribed in accordance with the applicable federal standards and contributes to reducing the severity of complications. Effectiveness data and pathogenetic considerations underpinning combination therapy with mexidol and other drugs suggest that this is a viable approach for treating cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma and alcohol intoxication as well as a number of other diseases.

Keywords:

mexidol
combination therapy
free radicals
lipid peroxidation
ischemic stroke
myocardial infarction
ischemic heart disease
epilepsy
alcohol intoxication

Authors:

Voronina T.A.

NII farmakologii im. V.V. Zakusova RAMN, Moskva

Ivanova E.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Close metadata

References:

  1. Mexidol for injection — official* instructions for use. Accessed February 20, 2019. (In Russ.) https://medi.ru/instrukciya/meksidol-dlya-inektsij_2601/
  2. Prikaz Ministerstva zdravoohraneniya Rossijskoj Federacii ot 29.12.12 g. №1740n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshchi pri infarkte mozga». Accessed February 20, 2019. (In Russ.) https://www.rosminzdrav.ru/documents/8970
  3. Registr lekarstvennyh sredstv Rossii. Accessed February 20, 2019. (In Russ) https://www.rlsnet.ru/tn_index_id_679.htm
  4. Spravochnik lekarstvennyh sredstv VIDAL. Accessed February 20, 2019. (In Russ.) https://www.vidal.ru/drugs/mexidol__39928
  5. Voronina TA. Novye napravleniya poiska nootropnyh preparatov (problemnaya stat’ya). Vestnik RAMN. 1998;(1):16-21. (In Russ.)
  6. Voronina TA. Antioxidant Mexidol. The basic neuropsychotropic effects and mechanism of action. Psychopharmacology and Biological Narcology. 2001;1(1):2-12. (In Russ.)
  7. Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Farmateka. 2009;180(6):1-4. (In Russ.)
  8. Dyumaev KM, Voronina TA, Smirnov LD. Antioksidanty v profilaktike i terapii patologij CNS. M.: Izd-vo In-ta biomed. himii. 1995. (In Russ.)
  9. Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39. (In Russ.)
  10. Luk’yanova LD, Atabaeva RE, Shepeleva SYu. Antihypoxic effects of some 3-hydroxypyridine derivatives in isolated rat myocardium. Bulletin of Experimental Biology and Medicine. 1993;115(3):259-260. (In Russ.)
  11. Luk’yanova LD. Sovremennye problemy gipoksii. Vestnik RAMN. 2000;9:3-12. (In Russ.)
  12. Yasnecov VV. Vliyanie nekotoryh nejrotropnyh veshchestv na dyhanie mitohondrij kletok golovnogo mozga krys. Vestnik Volgogradskogo Gosudarstvennogo Medicinskogo Universiteta. 2009;2:72-73. (In Russ.)
  13. Yasnecov VV. Protective effect of 3-hydroxy-pyridine derivatives in extreme conditions. Aviakosmicheskaya i Ekologicheskaya Meditsina. 2007;41(6):5-12. (In Russ)
  14. Kirova YuI, Germanova EL. New aspects of the energy-tropic action of mexidol. Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya. 2018;62(4):42-46. (In Russ.) https://doi.org/10.25557/0031-2991.2018.04.36-40
  15. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.)
  16. Voronina TA. Present-day problems in experimental psychopharmacology of nootropic drugs. Neuropharmacology. 1992;2:51-108.
  17. Sariev AK, Zherdev VP, Dvoryaninov AA, Voronina TA, Smirnov LD. Farmakokinetika vodorastvorimogo antioksidanta iz klassa 3-oksipiridina. Bulletin of Experimental Biology and Medicine. 1986;3:325-327. (In Russ.)
  18. Shchul’kin AV, Yakusheva EN, Chernykh IV. The distribution of mexidol in the rat’s brain and its subcellular fractions. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(8):70-73. (In Russ.)
  19. Usanova AA, Inchina VI, Zor’kina AV. Citoprotektory v korrekcii sochetannyh metabolicheskih narushenij. Saransk: Vektor-print; 2009. (In Russ.)
  20. Zhang L, Wang H. Targeting the NF-E2-Related Factor 2 Pathway: a Novel Strategy for Traumatic Brain Injury. Molecular Neurobiology. 2018;55(2):1773-1785. https://doi.org/10.1007/s12035-017-0456-z
  21. Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. An effect of mexidol on the expression of the transcription factor Nrf2 in cerebral cortex in ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):63-67. (In Russ.) https://doi.org/10.17116/jnevro20181186163-67
  22. Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. Mexidol effect on the factor induced by hypoxia HIF-1α expression in the rat cerebral cortex in its ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;10:62-66. (In Russ.) https://doi.org/10.17116/jnevro2017117101
  23. Semenza GL. O2 regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF1. Journal of Applied Physiology. 2004;96(3):1173-1177. https://doi.org/10.1152/japplphysiol.00770.2003
  24. Kuznecov YuV, Matyushin IA, Smirnov LD, Yasnecov VikV. Issledovanie antiokislitel’noj aktivnosti novyh analogov ehtilmetilgidroksipiridina sukcinata i proizvodnyh gidroksipirididobenzimidazola. Vestnik Novyh Medicinskih Tekhnologij. 2006;13(3):9-10. (In Russ.)
  25. Bashkatova V, Narkevich V, Vitskova G, Vanin A. The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiform model seizures. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2003;27:487-492. https://doi.org/10.1016/S0278-5846(03)00037-X
  26. Voronina TA, Kutepova OA. Experimentally established geropsychotropic properties of 3-hydroxypyridine antioxidant. Drug Development Research. 1988;14:353-358.
  27. Nootropic drugs in Alzheimer disease treatment. In: Giacobini E, Becker R, eds. Alzheimer Disease: Therapeutic Strategies. Proceedings of the Third International Springfield Alzheimer Symposium. Boston: Birkhauser Boston Inc; 1994.
  28. Seo MY, Lee SM. Protective effect of low dose of ascorbic acid on hepatobiliary function in hepatic ischemia/reperfusion in rats. Journal of Hepatology. 2002;36(1):72-77.
  29. Vozmozhnye mekhanizmy dejstviya membranoaktivnyh veshchestv s antioksidantnymi svojstvami v ehkstremal’nyh situaciyah. V kn.: Kletochnye mekhanizmy realizacii farmakologichekogo ehffekta. Pod red. Seredenina S.B. M. 1990. (In Russ.)
  30. Voronina TA, Seredenin SB. Analysis of the mechanism of psychotropic action of 3-hydroxypyridine derivative. Annali dell’Istituto Superiore di Sanita. 1988;24(3):461-466.
  31. Voronina TA, Smirnov LD, Dyumaev KM. Vliyanie membranomodulyatora iz klassa 3-oksipiridina na farmakologicheskuyu aktivnost’ psihotropnyh preparatov. Bulletin of Experimental Biology and Medicine. 1985;XCIX(5):519-522. (In Russ.)
  32. Voronina TA, Kutepova OA, Zolotov NN. Vliyanie antioksidantov iz klassa 3-oksipiridina na vyzvannoe ehtanolom narushenie obucheniya u myshej i nakoplenie lipofuscina. Bulletin of Experimental Biology and Medicine. 1989;3:314-316. (In Russ.)
  33. Smirnov LD, Voronina TA, Dyumaev KM, Rudenko GM, Morozov GV. Protivoalkogol’noe sredstvo. Patent SSSR 1777878/30.11.1992. Accessed February 20, 2019. (In Russ.) http://patents.su/2-1777878-protivoalkogolnoe-sredstvo.html
  34. Insul’t. Rukovodstvo dlya vrachej. Pod red. Stahovskoj L.V., Kotova S.V. M.: OOO «Medicinskoe informacionnoe agentstvo»; 2018. (In Russ.)
  35. Insul’t: sovremennye tekhnologii diagnostiki i lecheniya. Rukovodstvo dlya vrachej. Pod red. Piradova M.A., Tanashyan M.M., Maksimovoj M.Yu. M.: MEDpress-inform; 2018. (In Russ.)
  36. Seregin VI. Primenenie Gliatilina i Meksidola v intensivnoj terapii tyazhelogo ostrogo ishemicheskogo insul’ta. Farmateka. 2006; 120(5):24. (In Russ.)
  37. Skvorcova VI. Lechenie ostrogo ishemicheskogo insul’ta. Lechashchij vrach. 2004;7. Accessed February 20, 2019. (In Russ.) https://www.lvrach.ru/2004/07/4531538/
  38. Isajkin AI, Chernyshova EA, Yahno NN. Primenenie nejroprotektivnoj terapii pri insul’tah i cherepno-mozgovoj travme. Trudnyj pacient. 2012;10(11):18-21. Accessed February 20, 2019. (In Russ.) http://t-pacient.ru/articles/217/
  39. Gusev EI, Skvorcova VI. Ishemiya golovnogo mozga. M.: Medicina; 2001. (In Russ.)
  40. Vereshchagin NV, Piradov MA, Suslina ZA. Insul’t. Principy diagnostiki, lecheniya i profilaktiki. Kratkoe rukovodstvo dlya vrachej. M.: Intermedika; 2002. (In Russ.)
  41. Chefranova ZhYu, Makotrova TA, Udachin VA, Koledintseva EV. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(4):49-52. (In Russ.)
  42. Knni KS, Dyomin TV, Adeeva LB. Effect of mexidol on the efficiency of intravenous thrombolytic therapy for ischemic stroke during the therapeutic window. Nevrologiâ, Nejropsihiatriâ, Psihosomatika. 2018;10(3):86-90. (In Russ.)
  43. Skvortsova VI, Stakhovskaya LV, Nartzyssov YaR, Bodykhov MK, Kichuck IV, Gudkova YuV, Soldatenkova TD, Kondrasheva TT, Kalinina EV, Novichkova MD, Kerbikov OB. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (App. «Stroke»). 2006;18:47-54. (In Russ.)
  44. Lutskii MA. An analysis of mexidol efficacy in the complex treatment of patients with ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (App. «Stroke»). 2010;110(4-2):57-59. (In Russ.)
  45. Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskaya LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shchepankevich LA. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.) https://doi.org/10.17116/jnevro20171173255-65
  46. Izhbul’dina GI. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(3-2):31-37. (In Russ.)
  47. Berezhnaya SV, Yakupov EZ, Zaharov YuA. The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(5):23-27. (In Russ.) https://doi.org/10.17116/jnevro20161165123-27
  48. Shprakh VV, Matveeva IV, Spreis IF. Combined administration of amlodipine and mexidol in treatment early forms of chronic cerebral ischemia in coal mining workers. Byulleten’ VSNC SO RAMN. 2006;51(5):207-210. (In Russ.)
  49. Nechipurenko NI, Veres AI, Vasilevskaya LA, Pashkovskaya ID. Blood trace elements content and the condition of the dermal icrohaemodynamic in patients with dyscirculatory encephalopathy after the complex treatment with Mexidol. Nevrologiya i Nejrohirurgiya. Vostochnaya Evropa. 2011;3:98-108. (In Russ.)
  50. Bulahova EYu. Ispol’zovanie preparata meksidol dlya optimizacii lecheniya arterial’noj gipertenzii u bol’nyh molodogo vozrasta. Bulletin of Experimental biology and Medicine. 2006;(suppl 1):101-103. (In Russ.)
  51. Avakyan GG, Nerobkova LN, Oleynikova OM, Voronina TA, Avakyan GN, Gusev EI. Possibilities of application the prolonged form valproic acid and antioxidant in secondary-generalized seizures (clinical and experimental investigation). Epilepsia and Paroxyzmal Conditions. 2011;3(2):34-44. (In Russ.)
  52. Litvinovich EF. Klinicheskaya i farmako-ehkonomicheskaya ehffektivnost’ antioksidanta meksidola v kombinirovannoj patogeneticheskoj terapii bol’nyh s fokal’noj ehpilepsiej. Bulletin of Experimental Biology and Medicine. 2006;(suppl 1):45-47. (In Russ.)
  53. Korotkov AG. Primenenie preparata meksidol v kompleksnom lechenii bol’nyh farmakorezistentnoj parcial’noj ehpilepsiej. Bulletin of Experimental Biology and Medicine. 2006;(suppl 1):34-36. (In Russ.)
  54. Savenkov AA, Badalyan OL, Avakyan GN. Nootropics and antioxidants in the complex therapy of symptomatic posttraumatic epilepsy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;116(6):26-34. (In Russ.)
  55. Kurasov ES, Remizevich RS. The effect of mexidol in the combination with antidepressants on sleep disturbance in young patients with panic disorder. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(2):33-38. (In Russ.)
  56. Nikol’skaya IN, Khromova OM, Irkhina IS, Goncharova MV, Orlova NA. Comparative evaluation of clinical efficacy and safety of mexidol in patients with acute coronary syndrome in addition to standart regimen of treatment. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2013;6(3):37-42. (In Russ.)
  57. Zhestovskikh SS, Petrova LV, Ametov AS. Prevention and treatment of diabetes mellitus: current status (review). Therapeutic Archive. 2007;79(10):46-50. (In Russ.)
  58. Lankin VZ, Lisina MO, Arzamastseva NE, Konovalova GG, Nedosugova LV, Kaminnyi AI, Tikhaze AK, Ageev FT, Kukharchuk VV, Belenkov YuN. Oxidative stress in atherosclerosis and diabetes. Bulletin of Experimental Biology and Medicine. 2005;140(7):48-51. (In Russ.)
  59. Goryushkina OA, Vasilyeva EM. Antioxidant therapy in the correction of oxidative stress in the patients with coronary heart disease and type II diabetes. Journal of New Medical Technologies. 2013;(2):156. (In Russ.)
  60. Mihin VP. Kardiocitoprotektory — novoe napravlenie klinicheskoj kardiologii. Arhiv Vnutrennej Mediciny. 2011;1:21-28. (In Russ.)
  61. Zateyshchikov DA, Minushkina LO, Kudryashova OYU, Barinov VG, Tsimbalova TE, Nosenko EM, Sedov VP, Sidorenko BA. Functional state of endothelium in patients with hypertension and ischemic heart disease. Kardiologiia. 2000;40(2):14-17. (In Russ.)
  62. Borovkova NYu, Ilyina AS, Spassky AA, Borovkov NN, Kovaleva GV. Cytoprotective therapy for kidney injury in patients with ST-elevation myocardial infarction. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2017;10(1):38-41. (In Russ.) https://doi.org/10.17116/kardio201710138-41
  63. Mihin VP, Smirnov LD, Sernov LN. Sredstvo dlya lecheniya nestabil’noj stenokardii i ostrogo infarkta miokarda. Patent RF na izobretenie №2168993/11.05.2000. Byul. №17. Accessed February 20, 2019. (In Russ.) https://patents.google.com/patent/RU2168993C1/ru
  64. Volchegorskii IA, Tur EV, Solyannikova OV, Rykun VS, Sumina MS, Dmitrienko VN, Berdnikova EV. Effectiveness of 3-hydroxypyridine and succinic acid derivatives in complex treatment of primary open-angle glaucoma. Eksperimental’naia i Klinicheskaia Farmakologiia. 2012;75(7):20-26. (In Russ.)
  65. Egorov EA, Davydova NG, Romanenko IA, Novikova ND. Mexidol in complex treatment of glaucoma. RMZh. Klinicheskaya Oftal’mologiya. 2011;12(3):107-110. (In Russ.)
  66. Savlukov AI, Kildebekova RN, Farshatov RS. Coorection of lipid peroxydation and antioxydant protective system by mexidol and glycine in patiens with acute ethanol intoxication. Saratov Journal of Medical Scientifc Research. 2009;5(4):507-510. (In Russ.)
  67. Pharshatov RS, Haphysov NH, Kildibekova RN, Savlukov AI. Cognitive functions imapirement in patients with acute alcoholintoxication and their treatment with antioxydant drugs. Fundamental Research. 2012;7:208-210. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.